Unity Biotechnology and Mammoth Biosciences are both turning toward cost-saving measures, prompting layoffs at both companies ...

Truist lowered the firm’s price target on Regeneron (REGN) to $940 from $975 but keeps a Buy rating on the shares. The firm ...

We recently published a list of Billionaire Mario Gabelli’s 10 Large-Cap Stock Picks with Huge Upside Potential. In this ...

When a stock falls steadily on no news, that is a hint to avoid the company. Organon (OGN), a spin-off from Merck (MRK), continued to trade at a discount after posting results. The firm cut its ...

Oil prices dropped Monday, as the Organization of the Petroleum Exporting Countries and its allies agreed to boost output ...

These strategic moves, including the expansion of their key drug franchises like Dupixent and EYLEA, may positively impact revenue streams. With ongoing R&D investments and pipeline innovations, ...

Robert Radick writes his first health care enforcement roundup column for the NYLJ. "This new column will, every two months, ...

Mario Gabelli needs no introduction, having risen to become one of the most successful money managers on Wall Street, backed ...

Regeneron and Bayer are trying to fight back with a higher-dose version of Eylea that they hope will go longer between doses, while other companies with candidates in clinical development include ...

We recently published an article titled Jim Cramer Listed 20 Best Performing Stocks of the Last 20 Years. In this article, we ...